Campath and Drowsiness - a phase IV clinical study of FDA data

Summary:

Drowsiness is reported as a side effect among people who take Campath (alemtuzumab), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Fludara, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have Drowsiness when taking Campath. It is created by eHealthMe based on reports of 4,897 people who have side effects when taking Campath from the FDA, and is updated regularly.

What is Campath?

Campath has active ingredients of alemtuzumab. eHealthMe is studying from 4,909 Campath users. Check the latest studies of Campath.

What is Drowsiness?

Drowsiness is found to be associated with 2,865 drugs and 4,797 conditions by eHealthMe. Check the latest studies of Drowsiness.

On Jul, 20, 2026

4,897 people reported to have side effects when taking Campath.
Among them, 23 people (0.47%) have Drowsiness.

Among these 23 people:

How long have people been on Campath when they have Drowsiness? *

What is the gender of people who have Drowsiness when taking Campath? *

female: 26.09 %
male: 73.91 %

What is the age of people who have Drowsiness when taking Campath? *

What are other drugs people take besides Campath? *

What are other side effects people have besides Drowsiness? *

Weakness: 8 people, 34.78%
Fever: 7 people, 30.43%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 5 people, 21.74%
High Blood Pressure: 5 people, 21.74%
Meningitis Viral (viral inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges): 4 people, 17.39%
Agitation (state of anxiety or nervous excitement): 4 people, 17.39%
Nausea (feeling of having an urge to vomit): 4 people, 17.39%
Brain Herniation (brain herniation is a potentially deadly side effect of very high intracranial pressure that occurs when a part of the brain is squeezed across structures within the skull): 4 people, 17.39%
Confusion: 4 people, 17.39%
Mental Status Changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation): 4 people, 17.39%

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 6 people, 26.09%
Agitation (state of anxiety or nervous excitement): 2 people, 8.70%
Weakness: 1 person, 4.35%
Tremor (trembling or shaking movements in one or more parts of your body): 1 person, 4.35%
Peripheral T-Cell Lymphoma Unspecified (peripheral t-cell cancer unspecified): 1 person, 4.35%
Periodontal Disease (disease that attacks the gum and bone and around the teeth): 1 person, 4.35%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 4.35%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 4.35%
Lymphocytic Leukaemia (a type of cancer in which the bone marrow makes too many lymphocytes): 1 person, 4.35%
Leukaemia (blood or bone marrow cancer): 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Campath and have Drowsiness?

- Check whether Drowsiness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Campath:

Campath (4,909 reports)

Drowsiness treatments and more:

Drowsiness (269,040 reports)

Browse all side effects of Campath:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Drowsiness:

Drowsiness (2,865 drugs)

Browse all the conditions that are associated with Drowsiness:

Drowsiness (4,797 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on alemtuzumab (the active ingredients of Campath) and Campath (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.